Inositol 1,4,5-Trisphosphate Receptor Type 1 (ITPR1) Antibody, IgG by CBA-IFA With Reflex to Titer, CSF
Aids in the diagnosis of autoimmune cerebellar ataxia, encephalitis, neuropathy, and myelopathy. May be used to monitor treatment response in individuals who are antibody positive. The presence of ITPR1 antibodies may be associated with cerebellar ataxia, encephalitis with seizures, peripheral neuropathy, and myelopathy. ITPR1 antibody disease may be paraneoplastic, but tumor type is variable (eg, breast, lung, and renal cancers).
Semiquantitative Cell-Based Indirect Fluorescent Antibody
New York DOH Approval Status
Transfer 0.5 mL CSF to an ARUP standard transport tube. (Min: 0.15 mL)
Grossly hemolyzed or contaminated specimens.
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month (Three freeze/thaw cycles are acceptable)
Less than 1:1
Inositol 1, 4, 5-trisphosphate receptor type 1 (ITPR1) antibody is found in a subset of patients with autoimmune cerebellar ataxia, encephalitis, neuropathy, or myelopathy and may occur with or without associated tumor. A negative test result does not rule out a diagnosis of autoimmune cerebellar ataxia or related autoimmune neurologic disorders. Interpretation of any antineural antibody test requires clinical correlation.
This indirect fluorescent antibody assay utilizes ITPR1 transfected cell lines for detection and sem-quantification of ITPR1 IgG antibody.
Laboratory Developed Test (LDT)
If ITPR1 antibody IgG is positive, then ITPR1 antibody IgG titer will be added. Additional charges apply.
86255; if reflexed, add 86256
|Component Test Code*||Component Chart Name||LOINC|
|3006024||ITPR1 Ab IgG CBA-IFA Screen, CSF||96468-4|
- cerebellar ataxia
- ITPR 1
- movement disorder